The prevalence and laboratory characteristics of chronic hepatitis B in Moscow
- Авторлар: Voznesensky S.L1, Kozhevnikova G.M1, Chulanov V.P2, Golub V.P1
-
Мекемелер:
- Peoples' Friendship University of Russia
- Central Research Institute of Epidemiology, Russian Inspectorate for the Protection of Consumer Rights and Human Welfare
- Шығарылым: № 1 (2014)
- Беттер: 33-38
- Бөлім: Articles
- URL: https://journals.eco-vector.com/2226-6976/article/view/277335
- ID: 277335
Дәйексөз келтіру
Аннотация
The chronic viral hepatitis epidemic situation is not improving in the Russian Federation. Objective. To estimate the prevalence of active forms of chronic hepatitis B (CHB) to identify those who need specific antiviral therapy. Materials and methods. In 2003 to 2010, a total of 252614 people were examined for serum HBsAg and, if the latter was found, other markers characterizing the activity of CHB. The need for therapy was determined according to the European algorithm for the management of CHB patients. Clinical, epidemiological, laboratory (blood biochemical tests, serological and molecular biological assays) and statistical studies and instrumental diagnosis (fibroelastometry) were used. Results. The prevalence of ABsAg in the Moscow Region is 4.1%. CHB is most common in the active reproductive age groups 20-29 and 30-39 years. The relative proportion of HBsAg-positive women has considerably increased in recent years. The prevalence of HBsAg-positive hepatitis is 83.5%. Hepatitis B virus (HBV) DNA was found in 63.3% of the examined HBsAg-positive persons and the viral load was high in 20.0%. Enhanced alanine aminotransferase activity was recorded in 34.9% of the patients with detectable HBV DNA; it was more significantly noted in those with a high viral load. Conclusion. The large-scale survey of the Moscow Region’s population showed a higher proportion (4.1%) of HBsAg-positive persons than annual morbidity rates and that in the study conducted in the narrow indicator groups (donors and pregnant women). According to the results of clinical and laboratory studies with consideration for HBV DNA levels, antiviral therapy for CHB is recommended for almost a quarter of patients.
Негізгі сөздер
Толық мәтін
Авторлар туралы
S. Voznesensky
Peoples' Friendship University of Russia
Email: serriba@rambler.ru
G. Kozhevnikova
Peoples' Friendship University of Russia
Email: rudn-inf@yandex.ru
V. Chulanov
Central Research Institute of Epidemiology, Russian Inspectorate for the Protection of Consumer Rights and Human Welfare
Email: vladimir.chulanov@pcr.ru
V. Golub
Peoples' Friendship University of Russia
Email: golubvp@gmail.com
Әдебиет тізімі
- О состоянии санитарно-эпидемиологического благополучия населения в Российской Федерации в 2012 году: Государственный доклад. М.: Федеральный центр гигиены и эпидемиологии Роспотребнадзора, 2013. 176 с.
- Онищенко Г.Г., Жебрун А.Б. Вирусные гепатиты в Российской Федерации. Аналитический обзор. Справочник. СПБ: НИИЭМ им. Пастера, 2011. 116 с.
- http ://77. rospotrebnadzor. ru/index.php/san- epid
- Azam F., Koulaouzidis A. Hepatitis В virus and hepatocarcinogenesis. Ann. Hepatol. 2008; 7(2): 125-129.
- Bosch F.X., Ribes J., Cleries R., Diaz M. Epidemiology of hepatocellular carcinoma. Clin. Liver Dis. 2005; 9: 191-211.
- Keef E.B., Dieterich D.T., Han S.H., Jacobson I.M., Martin P., Schiff E.R. et al. Treatment algorithm for the management of chronic hepatitis B virus infection in the United States: An update. Clin. Gastroentorol. Hepatol. 2006; 4(8): 936-962.
- Liu T.T., Fang Y., Xiong H., Chen T.Y., Ni Z.P., Luo J.F. et al. A case-control study of the relationship between hepatitis B virus DNA level and risk of hepatocellular carcinoma in Qidong, China. World J. Gastroenterol. 2008; 14(19): 3059-3063.
- Вознесенский С.Л. Распространенность и клинико-лабораторная характеристика хронического гепатита В. Автореф. дис.. канд. мед. наук. М., 2013.
- Lok Anna S.F., McMahon B.J. Practice GUIDELINES by the American Association for the Study of Liver Diseases. Hepatology 2007; 45(2): 507-539.
- Шахгильдян И.В., Михайлов М.И., Онищенко Г.Г. Парентеральные вирусные гепатиты (эпидемиология, диагностика, профилактика). М.: ГОУ ВУНМЦ МЗ РФ, 2003. 384 с.
- Пенкина Т.В., Мельникова C.B., Васильев А.Ю., Чупыра Т.М. HBV-инфекция у сотрудников многопрофильного стационара. Медицинский вестник МВД 2007; 1(26): 30-34.
- Нагоев Б.С., Абидов М.Т., Понежева Ж.Б. Хронические вирусные гепатиты: иммунопатогенетические, клинико-диагностические и терапевтические аспекты. Майкоп: ГУРИПП «Адыгея», 2005. 304 с.
- Абдурахманов Д.Т. Хронический гепатит В и D. М.: ГЭОТАР-Медиа, 2010. 288 с.
- Вознесенский С.Л., Чуланов В.П., Кожевникова Г.М. Серологические и молекулярно-генетические показатели у лиц. Инфекционные болезни 2009; 7(приложение № 1): 44.
- EASL Clinical Practice Guidelines. J. Hepatol. 2012; 57: 167-185.
- Zacharakis G., Koskinas J., Kotsiou S., Pouliou E., Papoutselis M., Tzara F. et al. Natural history of chronic hepatitis B virus: a cohort study with up to 12 years’ follow-up in northern Greece. J. Med Virol. 2005; 77(2): 173-179.
- Chen G., Lin W., Shen F., Iloeje U.H., London W.T., Evans A.A. Past HBV viral Load as predictor of mortality and morbidity from HCC and Chronic Liver Disease in a Prospective Study. Am. J. Gastroentorol. 2006; 101(8): 1797-803.
- Noeje U.H., Yang H.I., Su J., Jen C.L., You S.L., Chen C.J. (The REVEAL-HBV Study Group) Predicting Cirrhosis Risk Based on the Level of Circulating Hepatitis B Viral Load. Gastroenterology 2006; 130: 678-686.
- Marcellin P., Ziol M., Bedossa P., Douvin C., Poupon R., De Lédinghen V. et al. Non-invasive assessment of liver fibrosis by stiffness measurement in patients with chronic hepatitis B. Liver Int. 2009; 29(2): 242-247.